Hepatic glucose utilization in hepatic steatosis and obesity
Hepatic glucose utilization in hepatic steatosis and obesity
复制标题
DOI：
10.1042/bsr20160381
复制
发表时间：
2016-12-01
影响因子：
4
通讯作者：
Peters, Adrien Michael
中科院分区：
文献类型：
--
作者：
Keramida, Georgia;Hunter, James;Peters, Adrien Michael
肝脏脂肪变性与肥胖和胰岛素抵抗有关。肝葡萄糖利用率（葡萄糖磷酸化率; MRglu）是否在脂肪变性和/或肥胖中增加尚不确定。我们的目的是确定脂肪变性和肥胖与MRglu的独立关系。60例常规PET/CT的患者在注射F-18-氟脱氧葡萄糖（FDG）后30分钟在腹部进行动态PET成像，然后使用腹主动脉进行动脉输入信号的肝脏Patlak-Rutland图形分析。将曲线梯度除以截距，得到归一化为肝脏FDG分布体积（ml/min/100 ml）的肝脏FDG清除率，并乘以血糖，得到肝脏MRglu（μ mol/min/100 ml）。肝脂肪变性定义为CT密度≥ 30 kg/m2。脂肪变性患者的肝脏MRglu（3.3 ± 1.3 μ mol/min/100 ml）高于非脂肪变性患者（1.7 ± 1.2 μ mol/min/100 ml; P
Hepatic steatosis is associated with obesity and insulin resistance. Whether hepatic glucose utilization rate (glucose phosphorylation rate; MRglu) is increased in steatosis and/or obesity is uncertain. Our aim was to determine the separate relationships of steatosis and obesity with MRglu. Sixty patients referred for routine PET/CT had dynamic PET imaging over the abdomen for 30 min post-injection of F-18-fluorodeoxyglucose (FDG), followed by Patlak-Rutland graphical analysis of the liver using abdominal aorta for arterial input signal. The plot gradient was divided by the intercept to give hepatic FDG clearance normalized to hepatic FDG distribution volume (ml/min per 100 ml) and multiplied by blood glucose to give hepatic MRglu (mu mol/min per 100 ml). Hepatic steatosis was defined as CT density of = 30 kg/m(2). Hepatic MRglu was higher in patients with steatosis (3.3+-1.3 mu mol/min per 100 ml) than those without (1.7+-1.2 mu mol/min per 100 ml; P